RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE

Viridian Therapeutics, Inc.\DEVRDN

Market cap
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss-8-11-13-27-33-42-111-79-130-238
Issuance of common stock under license agreement-0----68-6
Share-based compensation expense4322444142067
Amortization of Debt Issuance Costs and Discounts--------00
Depreciation and amortization0000000001
Accretion and amortization of premiums and discounts on available-for-sale securities----00-0-1011
Realized gain on investments-------0--
Loss on sale of equipment--------0--0
Net loss on extinguishment of debt---71,000-------0
Non-Cash Lease Expense--------000
Debt Extinguishment Expense---------1
Prepaid expenses and other assets-0-0-01-0-00132
Accounts payable----0-01-0212-12
Accrued and other liabilities----2115185
Unbilled revenue---------0-
Deferred revenue-------1-0-0
Loss on sale of equipment--------0--0
Non-Cash Lease Expense--------000
Other non cash items-------0---0
Prepaid expenses and other assets-0-0-01-0-00132
Accounts payable----0-01-0212-12
Accrued and other liabilities----2115185
Unbilled revenue---------0-
Deferred revenue-------1-0-0
Net cash used in operating activities-2-7-7-28-27-36-30-55-94-184
Purchases of short-term investments-------188223408
Proceeds from sales and maturities of short-term investments--------109315
Proceeds from sale of property and equipment-------0--
Purchases of property and equipment0000000011
Net cash used in investing activities-0-0-01-3028-50-74-115-94
Proceeds from Issuance of Common Stock---------15
Common Stock------17197
Preferred Stock------5135
Payment of issuance costs-----0----
Proceeds from Issuance of Private Placement---------76
Proceeds from Issuance of Convertible Preferred Stock------91-44-
Common Stock------17197
Preferred Stock------5135
Payment of issuance costs-----0----
Proceeds from Warrant Exercises--------12
Proceeds from Issuance of Convertible Preferred Stock------91-44-
Proceeds from Issuance of Secured Debt--------515
Proceeds from Warrant Exercises--------12
Payment of debt issuance costs--------0-
Proceeds from Issuance of Secured Debt--------515
Proceeds from Stock Options Exercised---000-1319
Payment of debt extinguishment costs---------1
Proceeds from Stock Plans-------001
Payment of debt issuance costs--------0-
Net cash provided by financing activities713-052420101125322226
Proceeds from Stock Options Exercised---000-1319
Proceeds from Stock Plans-------001
Net cash provided by financing activities713-052420101125322226
Net increase (decrease) in cash and cash equivalents------821-4113-53
Interest paid----010-01
Capital Expenditures Incurred but Not yet Paid-------00-
Amortization Of Stock Issuance Costs------000-
Stock Issuance Costs Included In Accrued Liabilities---------0
Stock Issuance Costs Included In Accounts Payable---------0
Notes Reduction---------5
Notes Issued---------5
Amortization Of Stock Issuance Costs------000-